Cannabis and nerve pain: what limited studies can tell us
Short answer: Research exists, but it is not a blanket endorsement of cannabis for nerve pain. NCCIH reports that one review of 16 studies--mostly of nabiximols, a specific THC/CBD mouth spray approved in some countries but not the United States--found possible pain relief versus placebo. NCCIH also cautions that the evidence was not reliable enough for firm conclusions: studies were small and may have been biased, and participants taking cannabinoid medicines were more likely to leave because of side effects.
Why "nerve pain" is not one treatment question
The studies summarized by NCCIH concern defined products and populations; they do not show that every cannabis flower, edible, vape, CBD product, or commercial label has the same effect. Nor do they tell an individual whether a product is appropriate with their diagnosis or medicines.
FDA distinguishes prescription cannabinoid medicines for specific indications from unapproved products marketed for other conditions. This page does not provide a dose or product choice. If you are weighing pain options, use the study limitations as a prompt to discuss the specific diagnosis, treatment goals, and medication list with a clinician or pharmacist. Do not replace prescribed treatment based on this summary.
For medicine-safety context, see cannabis and medication interactions.
Sources
- NCCIH: Cannabis and Cannabinoids -- neuropathic-pain and chronic-pain evidence summaries.
- FDA: Cannabis Research and Drug Approval Process -- scope of approved prescription medicines and limits for unapproved products.
The NCCIH evidence summary is U.S.-based; approvals and access differ by jurisdiction. This article is educational, not individualized medical advice.
Quick answers
Does the evidence prove cannabis treats nerve pain?
No. NCCIH describes limited studies of particular cannabinoid medicines; small samples, possible bias, and more side-effect dropouts limit certainty.
Does this identify a product or dose?
No. The sources do not identify a consumer product, amount, or schedule for an individual.